<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">1410</journal-id><journal-id journal-id-type="pmc-domain">jid</journal-id><journal-id journal-id-type="publisher-id">jid</journal-id><journal-title-group><journal-title>The Journal of Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">0022-1899</issn><issn pub-type="epub">1537-6613</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11481298</article-id><article-id pub-id-type="pmcid-ver">PMC11481298.1</article-id><article-id pub-id-type="pmcaid">11481298</article-id><article-id pub-id-type="pmcaiid">11481298</article-id><article-id pub-id-type="pmid">38819303</article-id><article-id pub-id-type="doi">10.1093/infdis/jiae289</article-id><article-id pub-id-type="publisher-id">jiae289</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject><subj-group subj-group-type="category-toc-heading"><subject>Bacteria</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00290</subject></subj-group></article-categories><title-group><article-title>Urgent Need to Understand and Prevent Gonococcal Infection: From the Laboratory to Real-World Context</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ruiz Garc&#237;a</surname><given-names initials="Y">Yara</given-names></name><aff>
<institution>GSK</institution>, <addr-line>Tres Cantos</addr-line>, <country country="ES">Spain</country></aff><xref rid="FM2" ref-type="author-notes"/><xref rid="jiae289-cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marrazzo</surname><given-names initials="J">Jeanne</given-names></name><aff>
<institution>University of Alabama at Birmingham, Birmingham, Alabama, USA</institution>
</aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9023-581X</contrib-id><name name-style="western"><surname>Martin&#243;n-Torres</surname><given-names initials="F">Federico</given-names></name><aff>
<institution>Translational Pediatrics and Infectious Diseases, Hospital Cl&#237;nico Universitario de Santiago de Compostela, Santiago de Compostela, Spain</institution>
</aff><aff>
<institution>Genetics, Vaccines and Infections Research Group, Instituto de Investigaci&#243;n Sanitaria de Santiago, University of Santiago de Compostela, Santiago de Compostela, Spain</institution>
</aff><aff>
<institution>Centro de Investigaci&#243;n Biom&#233;dica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III</institution>, <addr-line>Madrid</addr-line>, <country country="ES">Spain</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9918-9493</contrib-id><name name-style="western"><surname>Workowski</surname><given-names initials="K">Kimberly</given-names></name><aff>
<institution>Emory University</institution>, Atlanta, Georgia</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Giordano</surname><given-names initials="G">Giulia</given-names></name><aff>
<institution>GSK</institution>, <addr-line>Siena</addr-line>, <country country="IT">Italy</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pizza</surname><given-names initials="M">Mariagrazia</given-names></name><aff>
<institution>GSK</institution>, <addr-line>Siena</addr-line>, <country country="IT">Italy</country></aff><xref rid="jiae289-cor2" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sohn</surname><given-names initials="WY">Woo-Yun</given-names></name><aff>
<institution>GSK</institution>, Rockville, Maryland, USA</aff><xref rid="jiae289-FM10" ref-type="author-notes"/></contrib></contrib-group><author-notes><fn id="FM2"><p>Presented in part: European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 15&#8211;18 April 2023. Abstract 06426.</p></fn><corresp id="jiae289-cor2">Present affiliation: Imperial College, South Kensington, London, United Kingdom.</corresp><corresp id="jiae289-cor1">Correspondence: Yara Ruiz Garc&#237;a, MSc, PhD, Medical Affairs Department, Vaccines, GSK, Tres Cantos, Spain (<email>yruizg7@gmail.com</email>).</corresp><fn id="jiae289-FM10" fn-type="COI-statement"><p>
<bold>
<italic toggle="yes">Potential conflicts of interest</italic>.</bold> Y. R. G., G. G., and W-Y. S. are employed by GSK and hold shares in GSK. M. P. was employed by GSK at the time of the study, holds shares in GSK, and is now Visiting Professor at Imperial College London. J. M. reported payment to her institution from the National Institutes of Health (NIH) for conduct of phase 2 trial of Bexsero (a trademark owned by or licensed to GSK) in prevention of gonorrhea. F. M-T. has received honoraria from GSK, Pfizer Inc, Sanofi Pasteur, MSD, Seqirus, Biofabri, and Janssen for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work. F. M-T. has also acted as principal investigator in randomized controlled trials of the above-mentioned companies as well as Ablynx, Gilead, Regeneron, Roche, Abbott, Novavax, and MedImmune, with honoraria paid to his institution. K. W. reported payment from NIH for the conduct of a Bexsero clinical trial. The authors declare no other financial and non-financial relationships and activities.</p><p>All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</p></fn></author-notes><pub-date pub-type="collection"><day>15</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="epub" iso-8601-date="2024-05-31"><day>31</day><month>5</month><year>2024</year></pub-date><volume>230</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">472888</issue-id><fpage>e758</fpage><lpage>e767</lpage><history><date date-type="received"><day>26</day><month>4</month><year>2023</year></date><date date-type="editorial-decision"><day>16</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>30</day><month>5</month><year>2024</year></date><date date-type="corrected-typeset"><day>12</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>17</day><month>10</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-19 20:27:16.783"><day>19</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; GSK 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jiae289.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jiae289.pdf"/><abstract><title>Abstract</title><p>
<italic toggle="yes">Neisseria gonorrhoeae</italic> is widespread globally. Primary prevention is unsuccessful and antimicrobial resistance threatens optimal management. There is no specific vaccine and natural infection studies show that <italic toggle="yes">N gonorrhoeae</italic> can avoid and suppress immune responses. In addition to extensive variation in expression and specificity of many gonococcal surface antigens, it induces a robust inflammatory response through the Th17 pathway with a large influx of neutrophils and inflammatory cytokines but evades macrophages. The Th1- and Th2-mediated response is suppressed, resulting in low, short-lived antibody titers. Real-world evidence suggests that gonorrhea cases are reduced among recipients of <italic toggle="yes">Neisseria meningitidis</italic> group B vaccines containing outer membrane vesicles (OMVs). Although the first randomized trial of an OMV-containing MenB vaccine against <italic toggle="yes">N gonorrhoeae</italic> infection did not show statistically significant vaccine efficacy, ongoing trials might shed further light. Several candidate vaccine antigens for a gonococcal-specific vaccine are being evaluated preclinically but only one has reached clinical trials.</p></abstract><abstract abstract-type="teaser"><p>Gonorrhea is increasing in incidence globally; however, there is no vaccine available. This manuscript provides a description of the response of the immune system against gonococcal infections and potential vaccine mechanism of action to inform research and policy decisions.</p></abstract><kwd-group><kwd>gonorrhea</kwd><kwd><italic toggle="yes">Neisseria gonorrhoeae</italic></kwd><kwd>immunology</kwd><kwd><italic toggle="yes">Neisseria meningitidis</italic></kwd><kwd>vaccine</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>GlaxoSmithKline Biologicals SA</institution><institution-id institution-id-type="DOI">10.13039/100020955</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<italic toggle="yes">Neisseria gonorrhoeae</italic> is widespread globally, with an estimated 82 million new infections in individuals 15&#8211;49 years of age during 2020 [<xref rid="jiae289-B1" ref-type="bibr">1</xref>]. Most gonococcal infections occur in low- and middle-income countries, with the highest incidence in low-income countries [<xref rid="jiae289-B1" ref-type="bibr">1</xref>]. In developed countries, as with other sexually transmitted infections (STIs), the highest incidence is seen in adolescents and young adults, ethnic minority groups, and those of low socioeconomic status [<xref rid="jiae289-B2" ref-type="bibr">2</xref>, <xref rid="jiae289-B3" ref-type="bibr">3</xref>]. Other populations at particular risk of gonococcal infection include people with multiple sexual partners, people receiving preexposure prophylaxis (PrEP) therapy for human immunodeficiency virus, men who have sex with men, and people engaging in transactional sex [<xref rid="jiae289-B3" ref-type="bibr">3</xref>, <xref rid="jiae289-B4" ref-type="bibr">4</xref>]. Gonococcal infection is increasing in incidence [<xref rid="jiae289-B3" ref-type="bibr">3</xref>, <xref rid="jiae289-B4" ref-type="bibr">4</xref>]. Primary prevention measures (sexual abstinence or condom use) are not successful, and increases in antimicrobial resistance threaten the effectiveness of antibiotic treatment [<xref rid="jiae289-B3" ref-type="bibr">3</xref>, <xref rid="jiae289-B4" ref-type="bibr">4</xref>].</p><p>Unfortunately, there is no specific vaccine against gonococcal infection and there have been numerous challenges associated with the development of an effective vaccine. The classical approach to vaccine design is to mimic natural infection; however, the ability of <italic toggle="yes">N gonorrhoeae</italic> to avoid and suppress the immune response means that natural infection does not reliably induce immunity [<xref rid="jiae289-B5" ref-type="bibr">5</xref>]. In addition, there have been difficulties in implementing vaccine clinical trials due to frequent asymptomatic infections (notably in the pharynx and rectum), a limited infrastructure for providing care related to STIs, and social stigma related to STIs that can impact successful participation [<xref rid="jiae289-B5" ref-type="bibr">5</xref>].</p><p>We have conducted a narrative review with the purpose of assessing available evidence on gonococcal infection and the impact of the closely related <italic toggle="yes">Neisseria meningitidis</italic> group B vaccine in preventing gonorrhea.</p><sec id="jiae289-s0"><title>WHAT WE KNOW ABOUT THE IMMUNE RESPONSE TO <italic toggle="yes">N GONORRHOEAE</italic></title><p>The first stage in infection with <italic toggle="yes">N gonorrhoeae</italic> is bacterial adhesion to the mucosal epithelium, mediated through surface antigens including lipooligosaccharide (LOS), type IV pili, opacity proteins, and the major outer membrane protein, porin (Por) (<xref rid="jiae289-F1" ref-type="fig">Figure 1</xref>) [<xref rid="jiae289-B5" ref-type="bibr">5</xref>]. These surface antigens have an exceptional degree of variability as a result of genetic transformation [<xref rid="jiae289-B5" ref-type="bibr">5</xref>]. In addition, <italic toggle="yes">N gonorrhoeae</italic> can reversibly switch the expression of proteins on and off in a process known as phase variation [<xref rid="jiae289-B5" ref-type="bibr">5</xref>]. Together, these activities give the bacterium an unparalleled ability to evade the immune system.</p><fig position="float" id="jiae289-F1" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>Important antigens on the surface of <italic toggle="yes">Neisseria gonorrhoeae.</italic> Abbreviations: LOS, lipooligosaccharide; NHBA, neisserial heparin binding antigen; Opa, opacity protein; Por, porin.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jiae289f1.jpg"/></fig><p>Low titers of strain-specific antigonococcal local and systemic antibodies have been detected in men and women with uncomplicated genital infections [<xref rid="jiae289-B6" ref-type="bibr">6</xref>]. History of previous infections does not increase antibody titers, indicating no induction of immunological memory [<xref rid="jiae289-B6" ref-type="bibr">6</xref>]. Increased titers of anti-LOS antibodies have been seen in men experimentally infected with <italic toggle="yes">N gonorrhoeae</italic>, but there was no evidence of immunological memory upon reinfection [<xref rid="jiae289-B7" ref-type="bibr">7</xref>]. In contrast, there is a strong inflammatory response associated with gonococcal infection, manifested by a large influx of neutrophils [<xref rid="jiae289-B8" ref-type="bibr">8</xref>] and high levels of inflammatory cytokines such as interleukin (IL) 8, IL-6, IL-1&#946;, and tumor necrosis factor [<xref rid="jiae289-B9" ref-type="bibr">9</xref>].</p><p>Despite the large influx of neutrophils upon <italic toggle="yes">N gonorrhoeae</italic> infection, lack of immunoglobulin G (IgG) antibodies and inhibition of complement activation limit uptake of <italic toggle="yes">N gonorrhoeae</italic> by neutrophils [<xref rid="jiae289-B5" ref-type="bibr">5</xref>, <xref rid="jiae289-B10" ref-type="bibr">10</xref>]. Intracellular killing is resisted by mechanisms including suppression of oxidative burst, resistance to nonoxidative killing mechanisms, and production of lytic transglycosylases [<xref rid="jiae289-B5" ref-type="bibr">5</xref>, <xref rid="jiae289-B11" ref-type="bibr">11&#8211;13</xref>]. It is as yet unclear whether the neutrophil-driven inflammatory response to gonococcal infection benefits the bacterium or the host [<xref rid="jiae289-B14" ref-type="bibr">14</xref>].</p><p>Complement inactivation and down-regulation are also believed to play a major role in the mechanisms by which <italic toggle="yes">N gonorrhoeae</italic> evades the immune response. The complement cascade is inactivated by binding of the gonococcal LOS to C3b via lipid A [<xref rid="jiae289-B15" ref-type="bibr">15</xref>]. <italic toggle="yes">Neisseria gonorrhoeae</italic> uses its outer membrane Por molecules to bind the complement down-regulating proteins, C4b-binding protein and factor H, to evade killing by human complement [<xref rid="jiae289-B16" ref-type="bibr">16</xref>]. In addition, sialylation of gonococcal LOS enables <italic toggle="yes">N gonorrhoeae</italic> to bind factor H [<xref rid="jiae289-B16" ref-type="bibr">16</xref>]. Factor H usually acts to protect cells, as host structures bound to it are recognized as part of the host [<xref rid="jiae289-B15" ref-type="bibr">15</xref>]. Indeed, sialylation of LOS inhibits all 3 complement pathways [<xref rid="jiae289-B17" ref-type="bibr">17</xref>].</p><p>It is becoming increasingly recognized that the T-helper (Th) 17 proinflammatory response is promoted during gonococcal infection, suppressing cell-mediated Th1 and Th2 immune responses. Th17 cells characteristically produce IL-17 and it has been suggested that Th17 might have evolved to protect against pathogens that Th1 and Th2 responses are not effective against [<xref rid="jiae289-B18" ref-type="bibr">18</xref>]. A study in patients with gonorrhea found that IL-17A, IL-23, and interferon-&#947; were significantly elevated compared with healthy individuals [<xref rid="jiae289-B19" ref-type="bibr">19</xref>]. In another study, women with <italic toggle="yes">N gonorrhoeae</italic> or <italic toggle="yes">Chlamydia trachomatis</italic> infections had higher genital concentrations of cytokines, including IL-17, than women with no STI [<xref rid="jiae289-B20" ref-type="bibr">20</xref>]. The same researchers also reported significantly higher levels of IL-17 specifically in the genital secretions of women with <italic toggle="yes">N gonorrhoeae</italic> or <italic toggle="yes">C trachomatis</italic> compared with women with no STI [<xref rid="jiae289-B21" ref-type="bibr">21</xref>].</p><p>In mice, <italic toggle="yes">N gonorrhoeae</italic> has been shown to induce Th17 responses that promoted an influx of neutrophils and also recruited other innate defense mechanisms [<xref rid="jiae289-B22" ref-type="bibr">22</xref>]. In contrast, it suppressed Th1- and Th2-dependent adaptive responses through induction of transforming growth factor beta (TGF&#946;) [<xref rid="jiae289-B23" ref-type="bibr">23</xref>]. Importantly, treatment of mice with anti-TGF&#946; antibody during primary infection shifted the immune response away from Th17 toward Th1 and Th2 responses, promoted clearance of <italic toggle="yes">N gonorrhoeae</italic>, and aided development of Th1-dependent immune memory [<xref rid="jiae289-B24" ref-type="bibr">24</xref>]. Based on these findings, it has been proposed that <italic toggle="yes">N gonorrhoeae</italic> promotes Th17 responses that it can largely survive but suppresses Th1 and Th2 responses that might be able to eradicate it, suggesting that vaccine development should be based on strategies eliciting Th1- or Th2-dependent immune responses [<xref rid="jiae289-B24" ref-type="bibr">24</xref>].</p><p>Host risk factors and infection states also play a role in the immune response to <italic toggle="yes">N gonorrhoeae</italic>. There are major differences between men and women in the cellular lining of the urogenital tract, with different molecules acting as receptors for <italic toggle="yes">N gonorrhoeae</italic> and thus different mechanisms by which the gonococcus initiates infection in the urogenital tract [<xref rid="jiae289-B25" ref-type="bibr">25</xref>]. Genetic factors influencing host susceptibility to gonococcal infection might also play a role. This has been observed for <italic toggle="yes">N meningitidis</italic> for which a number of mutations are associated with increased susceptibility to disease and more severe outcomes; such mutations include those resulting in increased bacterial adhesion and reduced complement function [<xref rid="jiae289-B26" ref-type="bibr">26</xref>, <xref rid="jiae289-B27" ref-type="bibr">27</xref>]. However, to our knowledge, genetic factors influencing host susceptibility to <italic toggle="yes">N gonorrhoeae</italic> have not yet been identified.</p><p>It has been suggested that the adaptive immune response to <italic toggle="yes">N gonorrhoeae</italic> might depend on tissue penetration by the bacterium [<xref rid="jiae289-B5" ref-type="bibr">5</xref>], based on the observations that women with severe pelvic inflammatory disease (PID) have higher titers of antibodies [<xref rid="jiae289-B28" ref-type="bibr">28</xref>] and are protected against recurrence of PID [<xref rid="jiae289-B29" ref-type="bibr">29</xref>]. This would explain why most gonococcal infections of the lower urogenital tract, pharynx, and rectum, which are largely asymptomatic or cause little sustained tissue damage, are not associated with an immunologic memory response [<xref rid="jiae289-B5" ref-type="bibr">5</xref>].</p></sec><sec id="jiae289-s1"><title>EVIDENCE OF PROTECTION AGAINST <italic toggle="yes">N GONORRHOEAE</italic> WITH VACCINES AGAINST MENINGITIS B</title><p>There is currently no vaccine specifically targeting <italic toggle="yes">N gonorrhoeae</italic>. However, real-world evidence has suggested that a reduction in gonorrhea cases has been observed following vaccination programs against meningitis B (MenB), caused by <italic toggle="yes">N meningitidis</italic>. Data are available for 3 MenB vaccines containing outer membrane vesicles (OMVs): VA-MENGOC-BC, MeNZB, and 4CMenB. VA-MENGOC-BC is used in Cuba, MeNZB was widely used in New Zealand during an outbreak of MenB disease but is no longer available, and 4CMenB was first licensed in 2013 and is currently available in many countries. A comprehensive review article that summarizes the scientific and real-world evidence of MenB vaccines against gonorrhea has been published recently [<xref rid="jiae289-B30" ref-type="bibr">30</xref>]. Several independent observational studies have provided evidence that <italic toggle="yes">N meningitidis</italic> group B&#8211;derived OMV vaccines (MeNZB and 4CMenB) are associated with a reduced risk of contracting gonorrhea (<xref rid="jiae289-F2" ref-type="fig">Figure 2</xref>) [<xref rid="jiae289-B31" ref-type="bibr">31&#8211;38</xref>]. These results are subject to potential bias and limitations of observational studies. However, it is of interest to note that consistent results were reported across several studies assessing various geographies, populations, and using different methodologies. In addition, a modeling study of adolescent 4CMenB vaccination in England showed that vaccination could result in reductions in gonorrhea cases of 10%, 18%, and 25% over 10, 20, and 70 years, respectively, in individuals aged 13&#8211;64 years, based on 31% vaccine efficacy [<xref rid="jiae289-B39" ref-type="bibr">39</xref>].</p><fig position="float" id="jiae289-F2" fig-type="figure" orientation="portrait"><label>Figure 2.</label><caption><p>Current evidence for meningococcal group B outer membrane vesicle vaccines against <italic toggle="yes">Neisseria gonorrhoeae.</italic> Data from [<xref rid="jiae289-B31" ref-type="bibr">31&#8211;38</xref>, <xref rid="jiae289-B44" ref-type="bibr">44</xref>]. Abbreviations: CI, confidence interval; GC, gonococcal; HIV, human immunodeficiency virus; MSM, men who have sex with men; VE*, vaccine effectiveness (observational study); VE<sup>#</sup>, vaccine efficacy (clinical trial).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jiae289f2.jpg"/></fig><p>Supporting these findings, it has been shown in a female mouse model of <italic toggle="yes">N gonorrhoeae</italic> genital tract infection that immunization with 4CMenB speeded up clearance and reduced the burden of <italic toggle="yes">N gonorrhoeae</italic> compared with administration of placebo or alum [<xref rid="jiae289-B40" ref-type="bibr">40</xref>]. Vaccination with 4CMenB induced serum IgG and vaginal IgG and immunoglobulin A (IgA) that cross-reacted with <italic toggle="yes">N gonorrhoeae</italic> OMVs [<xref rid="jiae289-B40" ref-type="bibr">40</xref>]. Furthermore, antibodies from vaccinated mice recognized surface proteins from <italic toggle="yes">N gonorrhoeae</italic> including pili-associated protein Q and neisserial heparin binding antigen (NHBA) that are also detected in humans who have been immunized with 4CMenB [<xref rid="jiae289-B40" ref-type="bibr">40</xref>].</p><p>In Cuba, a major reduction of cases of <italic toggle="yes">N gonorrhoeae</italic> was seen following introduction of VA-MENGOC-BC [<xref rid="jiae289-B41" ref-type="bibr">41</xref>]. Intramuscular administration of VA-MENGOC-BC is known to induce a Th1 immune response characterized by induction of IgG and IgG1 but does not induce an IgA response [<xref rid="jiae289-B41" ref-type="bibr">41</xref>, <xref rid="jiae289-B42" ref-type="bibr">42</xref>]. Vaccines containing aluminum hydroxide normally induce a Th2 immune response, but this pattern is changed to a Th1 response in OMV-containing vaccines [<xref rid="jiae289-B41" ref-type="bibr">41</xref>]. Individuals vaccinated with VA-MENGOC-BC have serum IgG antibodies against <italic toggle="yes">N meningitidis</italic> proteoliposome (PL) but minimal IgA [<xref rid="jiae289-B41" ref-type="bibr">41</xref>]. In carriers of <italic toggle="yes">N meningitidis</italic>, a booster dose of VA-MENGOC-BC induced significantly higher levels of mucosal anti-PL IgA compared with noncarriers, as well as IgG and IgA that were cross-reactive to several gonococcal proteins [<xref rid="jiae289-B41" ref-type="bibr">41</xref>]. This suggests that natural carriage of <italic toggle="yes">N meningitidis</italic> in an immunized population might induce a mucosal immune response that impacts protection against acquiring gonorrhea [<xref rid="jiae289-B41" ref-type="bibr">41</xref>].</p><p>Several clinical trials of 4CMenB in prevention of gonorrhea are currently underway in countries including the United States, Thailand, Australia, Kenya, and Hong Kong (<xref rid="jiae289-F3" ref-type="fig">Figure 3</xref>). The first clinical trial to publish results was the National Agency for AIDS Research (ANRS) DOXYVAC trial, which assessed the effect of doxycycline postexposure prophylaxis (PEP) and 4CMenB against gonorrhea infection in men who have sex with men receiving PReP doxycycline therapy and with a history of an STI in the past 12 months. The results of the study were inconclusive. An interim analysis suggested a reduction in the number of cases of gonorrhea infection with both interventions, and the study was prematurely discontinued on the recommendation of the data and safety management board to offer doxycycline PEP and 4CMenB to all trial participants [<xref rid="jiae289-B43" ref-type="bibr">43</xref>]. However, the final, postaudit analysis of the study reported that vaccine efficacy of 4CMenB against gonorrhea infection did not meet statistical significance (22% [95% confidence interval, &#8722;1% to 40%]; <italic toggle="yes">P</italic> = .061) (<xref rid="jiae289-F2" ref-type="fig">Figure 2</xref>) [<xref rid="jiae289-B44" ref-type="bibr">44</xref>].</p><fig position="float" id="jiae289-F3" fig-type="figure" orientation="portrait"><label>Figure 3.</label><caption><p>Ongoing clinical trials of 4CMenB vaccine against gonorrhea. *Study timelines subject to change. Abbreviations: ACTRN, Australian Clinical Trials Registration Number; GBM+, gay bisexual men+ (men [cisgender and transgender], transgender women, and nonbinary people who have sex with men); IgG, immunoglobulin G; IMD, invasive meningococcal disease; KEMRI, Kenya Medical Research Institute; MSM, men who have sex with men; NCT, National Clinical Trial; NIAID, National Institute of Allergy and Infectious Diseases; NT, Northern Territory; OMV, outer membrane vesicle; RCT, randomized controlled trial.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jiae289f3.jpg"/></fig><sec id="jiae289-s1.1"><title>Potential Mechanism and Role of 4CMenB Vaccine Components in Gonorrhea Prevention</title><p>The 4CMenB vaccine contains 3 main recombinant <italic toggle="yes">Neisseria</italic> protein antigens: <italic toggle="yes">Neisseria</italic> adhesin A (NadA), NHBA, and variant 1 of factor H binding protein (fHbp), which were selected based on their ability to induce serum bactericidal antibodies to homologous and heterologous MenB strains [<xref rid="jiae289-B45" ref-type="bibr">45</xref>]. To increase immunogenicity, the accessory proteins, genome-derived <italic toggle="yes">Neisseria</italic> antigen (GNA) 1030 and GNA2091, are fused to NHBA and fHbp, respectively [<xref rid="jiae289-B46" ref-type="bibr">46</xref>]. The vaccine also contains OMVs derived from a MenB outbreak strain (B:4:P1.7&#8211;2.4) from New Zealand, which is the same OMV component used in the MeNZB vaccine that also demonstrated a protective effect against <italic toggle="yes">N gonorrhoeae</italic> [<xref rid="jiae289-B31" ref-type="bibr">31</xref>, <xref rid="jiae289-B32" ref-type="bibr">32</xref>]. OMVs contain several molecular moieties, but bactericidal antibodies are mainly produced against the porin protein, PorA [<xref rid="jiae289-B45" ref-type="bibr">45</xref>].</p><p>A study evaluating the prevalence of nucleotide and amino acid sequences of 4CMenB recombinant antigens in <italic toggle="yes">N gonorrhoeae</italic> isolates identified the presence of fHbp, NHBA, GNA2091, and GNA1030 genes but found that the NadA gene was absent [<xref rid="jiae289-B47" ref-type="bibr">47</xref>]. The <italic toggle="yes">N gonorrhoeae</italic> strains exhibited 67%&#8211;95% identity in nucleotide sequence and 61%&#8211;95% identity in amino acid sequence to the 4CMenB GNA antigens [<xref rid="jiae289-B47" ref-type="bibr">47</xref>]. However, truncated fHbp proteins were found in several isolates, resulting from premature stop codons in the genes [<xref rid="jiae289-B47" ref-type="bibr">47</xref>]. A recent bioinformatic analysis also investigated the similarity of 4CMenB antigens to gonococcal proteins [<xref rid="jiae289-B48" ref-type="bibr">48</xref>]. Of 22 core proteins in the OMV, 20 homologs were identified in <italic toggle="yes">N gonorrhoeae</italic>, of which 16 proteins had greater than 90% identity (<xref rid="jiae289-F4" ref-type="fig">Figure 4</xref>) [<xref rid="jiae289-B48" ref-type="bibr">48</xref>]. The analysis also demonstrated that homologs of fHbp, NHBA, GNA2091, and GNA1030 are conserved in <italic toggle="yes">N gonorrhoeae</italic> but the gene encoding NadA is missing, confirming previous findings [<xref rid="jiae289-B48" ref-type="bibr">48</xref>]. The analysis showed 68.8% identity of the NHBA antigen of 4CMenB to <italic toggle="yes">N gonorrhoeae</italic> (<xref rid="jiae289-F4" ref-type="fig">Figure 4</xref>) [<xref rid="jiae289-B48" ref-type="bibr">48</xref>]. As fHbp, GNA2091, and GNA1030 are not surface-exposed on <italic toggle="yes">N gonorrhoeae</italic>, NHBA and OMV are likely the only antigens in 4CMenB that provide a protective effect against <italic toggle="yes">N gonorrhoeae</italic> [<xref rid="jiae289-B48" ref-type="bibr">48</xref>].</p><fig position="float" id="jiae289-F4" fig-type="figure" orientation="portrait"><label>Figure 4.</label><caption><p>Homology of 4CMenB components to <italic toggle="yes">Neisseria gonorrhoeae</italic> proteins. From Semchenko et al [<xref rid="jiae289-B48" ref-type="bibr">48</xref>]. *fHbp is not expressed on the gonococcal surface; NadA is missing in gonococcus. Abbreviations: %ID, percent identity; ABC, ATP-binding cassette; AhpC, alkyl hydroperoxide reductase C; FbpA, ferric binding protein A; fHbp, factor H binding protein; FkpA, FKBP-type peptidyl-prolyl cis-trans isomerase; FrpB, Fe-regulated protein B; LbpA, lactoferrin binding protein A; LptD, lipopolysaccharide-assembly protein; LysM, lysin motif; MafA, multiple adhesin family A; MtrE, outer membrane efflux protein; NadA, <italic toggle="yes">Neisseria</italic> adhesin A; NHBA, neisserial heparin binding antigen; NMB, <italic toggle="yes">Neisseria meningitidis</italic> strain MC58; NspA, <italic toggle="yes">Neisseria gonorrhoeae</italic> surface protein A; OMP, outer membrane protein; OMV, outer membrane vesicle; OpcA, opacity protein A; PilQ, pili-associated protein Q; PorA, porin, serosubtype P1.4; PorB, porin, major OMP PIB; RmpM, reduction modifiable protein M; Tbp1, transferrin binding protein 1; Tfp, type IV pili; TSA, thiol-specific antioxidant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jiae289f4.jpg"/></fig><p>It should also be noted that 4CMenB is administered via the intramuscular route and could therefore be expected to elicit a strong immune response that natural infection, with just mucosal contact, cannot induce.</p></sec></sec><sec id="jiae289-s2"><title>ONGOING STUDIES OF GONORRHEA VACCINE CANDIDATES</title><p>Several candidate vaccine antigens are being evaluated in preclinical studies (<xref rid="jiae289-T1" ref-type="table">Table 1</xref>) [<xref rid="jiae289-B49" ref-type="bibr">49&#8211;58</xref>]. NHBA, a component of 4CMenB as described earlier, is also being investigated as an antigen for a stand-alone gonorrhea vaccine. Anti-NHBA antibodies promoted complement activation and facilitated bacterial killing through both serum bactericidal activity and opsonophagocytic activity (<xref rid="jiae289-T1" ref-type="table">Table 1</xref>) [<xref rid="jiae289-B49" ref-type="bibr">49</xref>]. The antibodies also prevented the functional activity of NHBA by reducing heparin binding and adherence to cervical and urethral epithelial cells [<xref rid="jiae289-B49" ref-type="bibr">49</xref>]. OMVs are also being investigated as platforms for a universal <italic toggle="yes">Neisseria</italic> vaccine, including an OMV with microencapsulated IL-12 as an adjuvant [<xref rid="jiae289-B50" ref-type="bibr">50</xref>], an OMV modified to overexpress a mutant fHbp and an attenuated endotoxin [<xref rid="jiae289-B51" ref-type="bibr">51</xref>], detoxified OMVs as immunogens [<xref rid="jiae289-B52" ref-type="bibr">52</xref>], and an OMV genetically modified from a circulating gonococcal strain [<xref rid="jiae289-B53" ref-type="bibr">53</xref>] (<xref rid="jiae289-T1" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="jiae289-T1" orientation="portrait"><label>Table 1.</label><caption><p>Studies of Current Gonorrhea Vaccine Candidate Antigens in Preclinical Development</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Description</th><th align="center" rowspan="1" colspan="1">Study Findings</th><th align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Neisserial heparin binding antigen</td><td rowspan="1" colspan="1">Promoted complement activation, facilitated bacterial killing, reduced heparin binding, reduced adherence of NHBA to epithelial cells</td><td rowspan="1" colspan="1">Semchenko et al, 2020 [<xref rid="jiae289-B49" ref-type="bibr">49</xref>]</td></tr><tr><td rowspan="1" colspan="1">Gonococcal OMV with microencapsulated IL-12</td><td rowspan="1" colspan="1">Faster clearance of gonococcal infection in mice compared with control. Generation of IgG and IgA antibodies against antigens from homologous and heterologous strains</td><td rowspan="1" colspan="1">Liu et al, 2017 [<xref rid="jiae289-B50" ref-type="bibr">50</xref>]</td></tr><tr><td rowspan="1" colspan="1">Meningococcal OMV with attenuated endotoxin and overexpressing fHbp</td><td rowspan="1" colspan="1">Elicited human complement-mediated serum bactericidal antibody responses against a gonococcal strain</td><td rowspan="1" colspan="1">Beernink et al, 2019 [<xref rid="jiae289-B51" ref-type="bibr">51</xref>]</td></tr><tr><td rowspan="1" colspan="1">Meningococcal detoxified OMV from strains lacking the major outer membrane proteins (PorA, PorB, and RmpM)</td><td rowspan="1" colspan="1">Enhanced gonococcal clearance in immunized mice. Clearance was associated with <italic toggle="yes">Neisseria meningitidis</italic> IgG antibodies that cross-reacted with <italic toggle="yes">Neisseria gonorrhoeae</italic></td><td rowspan="1" colspan="1">Matthias et al, 2022 [<xref rid="jiae289-B52" ref-type="bibr">52</xref>]</td></tr><tr><td rowspan="1" colspan="1">Two candidate vaccines based on a gonococcal OMV developed from recent Chilean strain and laboratory strain</td><td rowspan="1" colspan="1">Both candidates induced gonococcal-specific serum and mucosal IgG and IgA antibodies, as well as gonococcal-specific Th1/Th17 responses in mice. Both accelerated clearance of infection faster than 4CMenB</td><td rowspan="1" colspan="1">MacLennan et al, 2022 [<xref rid="jiae289-B53" ref-type="bibr">53</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Salmonella enteriditis</italic> ghost delivering <italic toggle="yes">N gonorrhoeae</italic> PorB-based DNA vaccine</td><td rowspan="1" colspan="1">Elicited higher CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses and IgG responses compared with DNA vaccine alone in mice, along with a rise in bactericidal antibody titer</td><td rowspan="1" colspan="1">Jiao et al, 2018 [<xref rid="jiae289-B54" ref-type="bibr">54</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">Salmonella enteriditis</italic> ghost delivering <italic toggle="yes">N gonorrhoeae N</italic>spA-based DNA vaccine</td><td rowspan="1" colspan="1">Elicited high levels of anti-NspA antibodies and bactericidal antibodies in immunized mice; antibodies were highest in mice coadministered both the NspA-based and PorB-based vaccine</td><td rowspan="1" colspan="1">Jiao et al, 2021 [<xref rid="jiae289-B55" ref-type="bibr">55</xref>]</td></tr><tr><td rowspan="1" colspan="1">Hybrid antigen of <italic toggle="yes">N gonorrhoeae</italic> TbpB used as a scaffold to display conserved surface epitopes of TbpA</td><td rowspan="1" colspan="1">Antisera raised in mice and rabbits against the hybrid antigens recognized surface TbpA of <italic toggle="yes">N meningitidis</italic> and inhibited transferrin-dependent growth</td><td rowspan="1" colspan="1">Fegan et al, 2019 [<xref rid="jiae289-B56" ref-type="bibr">56</xref>]</td></tr><tr><td rowspan="1" colspan="1">Peptide mimic (mimitope) of LOS epitope 2C7 with Toll-like receptor 4 and Th1-stimulating adjuvant</td><td rowspan="1" colspan="1">Elicited bactericidal IgG, as well as reducing colonization levels and accelerating clearance of gonococci in infected mice</td><td rowspan="1" colspan="1">Gulati et al, 2019 [<xref rid="jiae289-B57" ref-type="bibr">57</xref>]</td></tr><tr><td rowspan="1" colspan="1">Microneedle-based transdermal delivery of whole-cell inactivated <italic toggle="yes">N gonorrhoeae</italic> microparticles</td><td rowspan="1" colspan="1">Higher antigen-specific IgG antibody titers and antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cells in mice versus gonococcal antigens in solution or empty microneedles</td><td rowspan="1" colspan="1">Gala et al, 2018 [<xref rid="jiae289-B58" ref-type="bibr">58</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>Abbreviations: fHbp, factor H binding protein; IgA, immunoglobulin A; IgG, immunoglobulin G; IL, interleukin; LOS, lipooligosaccharide; NHBA, neisserial heparin binding antigen; NspA, Neisserial surface protein A; OMV, outer membrane vesicle; Por, porin; RmpM, reduction modifiable protein M; Tbp, transferrin binding protein; Th1, T-helper 1 cell; Th17, T-helper 17 cell.</p></fn></table-wrap-foot></table-wrap><p>Bacterial ghosts are also being evaluated for use in gonococcal vaccines. Ghosts are empty shells of gram-negative bacteria that have an identical antigenic profile to the original bacterium and can be used for immunization with envelope antigens or as delivery vehicles for other molecules [<xref rid="jiae289-B59" ref-type="bibr">59</xref>]. Ghosts have been used for delivery of an <italic toggle="yes">N gonorrhoeae</italic> PorB-based DNA vaccine and a neisserial surface protein A&#8211;based vaccine (<xref rid="jiae289-T1" ref-type="table">Table 1</xref>) [<xref rid="jiae289-B54" ref-type="bibr">54</xref>, <xref rid="jiae289-B55" ref-type="bibr">55</xref>]. The surface transferrin receptor proteins are important in the survival of <italic toggle="yes">N gonorrhoeae</italic> in the genitourinary tract of men and are therefore potential vaccine targets [<xref rid="jiae289-B56" ref-type="bibr">56</xref>]. Transferrin binding protein B has been used as a scaffold to display conserved surface epitopes from transferrin binding protein A, which is an integral outer membrane protein [<xref rid="jiae289-B56" ref-type="bibr">56</xref>]. The resulting hybrid antigen elicited protection against bacterial challenge in mice (<xref rid="jiae289-T1" ref-type="table">Table 1</xref>) [<xref rid="jiae289-B56" ref-type="bibr">56</xref>].</p><p>The 2C7 epitope of gonococcal LOS is conserved among gonococci and is immunogenic during natural infection, making it a potentially useful epitope as a vaccine antigen [<xref rid="jiae289-B60" ref-type="bibr">60</xref>]. Immunization with 2C7-generated antibodies accelerated gonococcal clearance in infected mice (<xref rid="jiae289-T1" ref-type="table">Table 1</xref>) [<xref rid="jiae289-B57" ref-type="bibr">57</xref>]. A further approach being investigated is microneedle-based transdermal delivery of whole-cell inactivated <italic toggle="yes">N gonorrhoeae</italic> microparticles (<xref rid="jiae289-T1" ref-type="table">Table 1</xref>) [<xref rid="jiae289-B58" ref-type="bibr">58</xref>].</p><p>Only one candidate vaccine, the <italic toggle="yes">N gonorrhoeae</italic> generalized modules for membrane antigens vaccine, has reached a phase 1/2 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05630859">NCT05630859</ext-link>). Potential next steps in the development of a gonococcal-specific vaccine are described in <xref rid="jiae289-box1" ref-type="boxed-text">Box 1</xref>.</p><boxed-text id="jiae289-box1" position="float" orientation="portrait"><label>Box 1:</label><caption><title>Next Steps in Development of a Gonococcal Vaccine</title></caption><table-wrap position="anchor" id="jiae289-T1a" orientation="portrait"><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/></colgroup><tbody><tr><td rowspan="1" colspan="1">Ongoing trials of MenB vaccine in preventing gonorrhea can provide good infrastructure and opportunity for further research:<list list-type="bullet"><list-item><p>Study of <italic toggle="yes">Neisseria gonorrhoeae</italic> Th17-driven responses and suppression of Th1- and Th2-driven responses</p></list-item><list-item><p>Study of the immunogenetics of vaccinated individuals to understand and identify the immunodominant epitopes in the vaccine that explain the improved immune protection against gonococcal infection compared with naturally infected individuals</p></list-item><list-item><p>Immune evasion in vaccinated individuals who acquire gonococcal infection</p></list-item><list-item><p>Identification of correlates of protection</p></list-item></list></td></tr><tr><td rowspan="1" colspan="1">Confirm that the immunosuppressive pathways identified in mice are repeated in humans</td></tr><tr><td rowspan="1" colspan="1">Investigate Th1-driven responses induced by new vaccine candidates</td></tr><tr><td rowspan="1" colspan="1">Evaluate novel adjuvants and delivery systems to optimize mucosal responses to candidate vaccines</td></tr><tr><td rowspan="1" colspan="1">Adapt multiorgan cultures to combine primary human epithelial and immune cells to study human immune responses during infection</td></tr><tr><td rowspan="1" colspan="1">Further investigate the pathogenesis of <italic toggle="yes">N gonorrhoeae</italic> in the absence and presence of <italic toggle="yes">Chlamydia trachomatis</italic></td></tr></tbody></table></table-wrap></boxed-text></sec><sec sec-type="conclusions" id="jiae289-s3"><title>CONCLUSIONS</title><p>The challenge for gonococcal vaccine development is that natural infection does not reliably induce immunity, and thus the classical approach of vaccine design, mimicking natural infection, is challenging. To develop vaccines with a superior protective immune response than that induced by natural infection, we need a better understanding of how <italic toggle="yes">N gonorrhoeae</italic> avoids inducing an effective immune response. Vaccines able to maintain Th1 response might be promising. However, work into potential candidate vaccine antigens is still at a very early stage and there is only one ongoing clinical trial in humans. Meanwhile, investigation of an apparent protective effect of MenB OMV vaccines is a high priority and clinical trials to further assess the effect of 4CMenB against gonorrhea are ongoing. Such trials should provide good infrastructure and opportunity for further research into immune responses and immune evasion of <italic toggle="yes">N gonorrhoeae</italic>.</p></sec></body><back><sec id="jiae289-s4"><title>Notes</title><p>
<bold>
<italic toggle="yes">Acknowledgments.</italic>
</bold> The authors thank Erika Bartolini, Gaurav Mathur, Marta Palla, Ashley Broom, and Zeki Kocaata for their review of the manuscript. The authors also thank Business and Decision Life Sciences Medical Communication Service Center for editorial assistance and manuscript coordination, on behalf of GSK. Mary L. Greenacre (An Sgriobhadair, UK) provided medical writing services.</p><p>
<bold>
<italic toggle="yes">Author contributions.</italic>
</bold> Y. R. G. conceived this review. All authors participated in the interpretation of the data and the development of this manuscript. All authors had full access to the data and gave final approval before submission.</p><p>
<bold>
<italic toggle="yes">Financial support</italic>.</bold> GlaxoSmithKline Biologicals SA funded this literature review and took in charge all costs associated with the development and publication of this manuscript including the Open Access publication charges.</p></sec><ref-list id="ref1"><title>References</title><ref id="jiae289-B1"><label>1</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <article-title>Global progress report on HIV, viral hepatitis and sexually transmitted infections</article-title>. <year>2021</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/i/item/9789240027077" ext-link-type="uri">https://www.who.int/publications/i/item/9789240027077</ext-link>. Accessed August 2022.</mixed-citation></ref><ref id="jiae289-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kirkcaldy</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Weston</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Segurado</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Hughes</surname><given-names>G</given-names></string-name></person-group>. <article-title>Epidemiology of gonorrhoea: a global perspective</article-title>. <source>Sex Health</source><year>2019</year>; <volume>16</volume>:<fpage>401</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">31505159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1071/SH19061</pub-id><pub-id pub-id-type="pmcid">PMC7064409</pub-id></mixed-citation></ref><ref id="jiae289-B3"><label>3</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/std/statistics/2022/overview.htm" ext-link-type="uri">https://www.cdc.gov/std/statistics/2022/overview.htm</ext-link>. <date-in-citation content-type="access">Accessed 31 July 2024</date-in-citation>.</mixed-citation></ref><ref id="jiae289-B4"><label>4</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/i/item/9789240039827" ext-link-type="uri">https://www.who.int/publications/i/item/9789240039827</ext-link>. Accessed August 2022.</mixed-citation></ref><ref id="jiae289-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Russell</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Jerse</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Gray-Owen</surname><given-names>SD</given-names></string-name></person-group>. <article-title>Progress toward a gonococcal vaccine: the way forward</article-title>. <source>Front Immunol</source><year>2019</year>; <volume>10</volume>:<fpage>2417</fpage>.<pub-id pub-id-type="pmid">31681305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.02417</pub-id><pub-id pub-id-type="pmcid">PMC6803597</pub-id></mixed-citation></ref><ref id="jiae289-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hedges</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Mayo</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Mestecky</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hook</surname><given-names>EW</given-names><suffix>3rd</suffix></string-name>, <string-name name-style="western"><surname>Russell</surname><given-names>MW</given-names></string-name></person-group>. <article-title>Limited local and systemic antibody responses to <italic toggle="yes">Neisseria gonorrhoeae</italic> during uncomplicated genital infections</article-title>. <source>Infect Immun</source><year>1999</year>; <volume>67</volume>:<fpage>3937</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">10417159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.67.8.3937-3946.1999</pub-id><pub-id pub-id-type="pmcid">PMC96675</pub-id></mixed-citation></ref><ref id="jiae289-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schmidt</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lindstrom</surname><given-names>JA</given-names></string-name>, <etal>et al</etal></person-group><article-title>Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers</article-title>. <source>Sex Transm Dis</source><year>2001</year>; <volume>28</volume>:<fpage>555</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">11689753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007435-200110000-00001</pub-id></mixed-citation></ref><ref id="jiae289-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Simons</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Nauseef</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Apicella</surname><given-names>MA</given-names></string-name></person-group>. <article-title>Interactions of <italic toggle="yes">Neisseria gonorrhoeae</italic> with adherent polymorphonuclear leukocytes</article-title>. <source>Infect Immun</source><year>2005</year>; <volume>73</volume>:<fpage>1971</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15784537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.73.4.1971-1977.2005</pub-id><pub-id pub-id-type="pmcid">PMC1087443</pub-id></mixed-citation></ref><ref id="jiae289-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ramsey</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cross</surname><given-names>AS</given-names></string-name>, <etal>et al</etal></person-group><article-title>Inflammatory cytokines produced in response to experimental human gonorrhea</article-title>. <source>J Infect Dis</source><year>1995</year>; <volume>172</volume>:<fpage>186</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">7797909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/172.1.186</pub-id></mixed-citation></ref><ref id="jiae289-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rest</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Frangipane</surname><given-names>JV</given-names></string-name></person-group>. <article-title>Growth of <italic toggle="yes">Neisseria gonorrhoeae</italic> in CMP-<italic toggle="yes">N</italic>-acetylneuraminic acid inhibits nonopsonic (opacity-associated outer membrane protein-mediated) interactions with human neutrophils</article-title>. <source>Infect Immun</source><year>1992</year>; <volume>60</volume>:<fpage>989</fpage>&#8211;<lpage>97</lpage>.<pub-id pub-id-type="pmid">1541573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.60.3.989-997.1992</pub-id><pub-id pub-id-type="pmcid">PMC257585</pub-id></mixed-citation></ref><ref id="jiae289-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Criss</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Seifert</surname><given-names>HS</given-names></string-name></person-group>. <article-title><italic toggle="yes">Neisseria gonorrhoeae</italic> suppresses the oxidative burst of human polymorphonuclear leukocytes</article-title>. <source>Cell Microbiol</source><year>2008</year>; <volume>10</volume>:<fpage>2257</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">18684112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1462-5822.2008.01205.x</pub-id><pub-id pub-id-type="pmcid">PMC2692872</pub-id></mixed-citation></ref><ref id="jiae289-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Criss</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Katz</surname><given-names>BZ</given-names></string-name>, <string-name name-style="western"><surname>Seifert</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Resistance of <italic toggle="yes">Neisseria gonorrhoeae</italic> to non-oxidative killing by adherent human polymorphonuclear leucocytes</article-title>. <source>Cell Microbiol</source><year>2009</year>; <volume>11</volume>:<fpage>1074</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">19290914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1462-5822.2009.01308.x</pub-id><pub-id pub-id-type="pmcid">PMC2771623</pub-id></mixed-citation></ref><ref id="jiae289-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ragland</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Schaub</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Hackett</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Dillard</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Criss</surname><given-names>AK</given-names></string-name></person-group>. <article-title>Two lytic transglycosylases in <italic toggle="yes">Neisseria gonorrhoeae</italic> impart resistance to killing by lysozyme and human neutrophils</article-title>. <source>Cell Microbiol</source><year>2017</year>; <volume>19</volume>:<fpage>e12662</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cmi.12662</pub-id><pub-id pub-id-type="pmcid">PMC5303151</pub-id><pub-id pub-id-type="pmid">27597434</pub-id></mixed-citation></ref><ref id="jiae289-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Criss</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Genco</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Gray-Owen</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Jerse</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Seifert</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Challenges and controversies concerning <italic toggle="yes">Neisseria gonorrhoeae</italic>&#8211;neutrophil interactions in pathogenesis</article-title>. <source>mBio</source><year>2021</year>; <volume>12</volume>:<fpage>e0072121</fpage>.<pub-id pub-id-type="pmid">34060328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.00721-21</pub-id><pub-id pub-id-type="pmcid">PMC8262874</pub-id></mixed-citation></ref><ref id="jiae289-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Quillin</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Seifert</surname><given-names>HS</given-names></string-name></person-group>. <article-title><italic toggle="yes">Neisseria gonorrhoeae</italic> host adaptation and pathogenesis</article-title>. <source>Nat Rev Microbiol</source><year>2018</year>; <volume>16</volume>:<fpage>226</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">29430011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro.2017.169</pub-id><pub-id pub-id-type="pmcid">PMC6329377</pub-id></mixed-citation></ref><ref id="jiae289-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ram</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cullinane</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Blom</surname><given-names>AM</given-names></string-name>, <etal>et al</etal></person-group><article-title>Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of <italic toggle="yes">Neisseria gonorrhoeae</italic></article-title>. <source>J Exp Med</source><year>2001</year>; <volume>193</volume>:<fpage>281</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">11157049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.193.3.281</pub-id><pub-id pub-id-type="pmcid">PMC2195916</pub-id></mixed-citation></ref><ref id="jiae289-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ram</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shaughnessy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>de Oliveira</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Gulati</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rice</surname><given-names>PA</given-names></string-name></person-group>. <article-title>Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics</article-title>. <source>Pathog Dis</source><year>2017</year>; <volume>75</volume>:<fpage>ftx049</fpage>.<pub-id pub-id-type="pmid">28460033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/femspd/ftx049</pub-id><pub-id pub-id-type="pmcid">PMC5449626</pub-id></mixed-citation></ref><ref id="jiae289-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tesmer</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Lundy</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Sarkar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>DA</given-names></string-name></person-group>. <article-title>Th17 cells in human disease</article-title>. <source>Immunol Rev</source><year>2008</year>; <volume>223</volume>:<fpage>87</fpage>&#8211;<lpage>113</lpage>.<pub-id pub-id-type="pmid">18613831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-065X.2008.00628.x</pub-id><pub-id pub-id-type="pmcid">PMC3299089</pub-id></mixed-citation></ref><ref id="jiae289-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gagliardi</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Starnino</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Teloni</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group><article-title>Circulating levels of interleukin-17A and interleukin-23 are increased in patients with gonococcal infection</article-title>. <source>FEMS Immunol Med Microbiol</source><year>2011</year>; <volume>61</volume>:<fpage>129</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">21214637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1574-695X.2010.00759.x</pub-id></mixed-citation></ref><ref id="jiae289-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Masson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mlisana</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Little</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group><article-title>Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study</article-title>. <source>Sex Transm Infect</source><year>2014</year>; <volume>90</volume>:<fpage>580</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">25107710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/sextrans-2014-051601</pub-id></mixed-citation></ref><ref id="jiae289-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Masson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Salkinder</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Olivier</surname><given-names>AJ</given-names></string-name>, <etal>et al</etal></person-group><article-title>Relationship between female genital tract infections, mucosal interleukin-17 production and local T helper type 17 cells</article-title>. <source>Immunology</source><year>2015</year>; <volume>146</volume>:<fpage>557</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="pmid">26302175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imm.12527</pub-id><pub-id pub-id-type="pmcid">PMC4693890</pub-id></mixed-citation></ref><ref id="jiae289-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feinen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jerse</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Gaffen</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Russell</surname><given-names>MW</given-names></string-name></person-group>. <article-title>Critical role of Th17 responses in a murine model of <italic toggle="yes">Neisseria gonorrhoeae</italic> genital infection</article-title>. <source>Mucosal Immunol</source><year>2010</year>; <volume>3</volume>:<fpage>312</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">20107432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mi.2009.139</pub-id><pub-id pub-id-type="pmcid">PMC2857675</pub-id></mixed-citation></ref><ref id="jiae289-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Islam</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Jarvis</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Gray-Owen</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Russell</surname><given-names>MW</given-names></string-name></person-group>. <article-title><italic toggle="yes">Neisseria gonorrhoeae</italic> selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-&#946;-dependent mechanisms</article-title>. <source>Mucosal Immunol</source><year>2012</year>; <volume>5</volume>:<fpage>320</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="pmid">22354319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mi.2012.12</pub-id><pub-id pub-id-type="pmcid">PMC3328619</pub-id></mixed-citation></ref><ref id="jiae289-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Russell</surname><given-names>MW</given-names></string-name></person-group>. <article-title>Diversion of the immune response to <italic toggle="yes">Neisseria gonorrhoeae</italic> from Th17 to Th1/Th2 by treatment with anti-transforming growth factor &#946; antibody generates immunological memory and protective immunity</article-title>. <source>mBio</source><year>2011</year>; <volume>2</volume>:<fpage>e00095-11</fpage>.<pub-id pub-id-type="pmid">21610119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.00095-11</pub-id><pub-id pub-id-type="pmcid">PMC3101786</pub-id></mixed-citation></ref><ref id="jiae289-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Edwards</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Apicella</surname><given-names>MA</given-names></string-name></person-group>. <article-title>The molecular mechanisms used by <italic toggle="yes">Neisseria gonorrhoeae</italic> to initiate infection differ between men and women</article-title>. <source>Clin Microbiol Rev</source><year>2004</year>; <volume>17</volume>:<fpage>965</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">15489357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.17.4.965-981.2004</pub-id><pub-id pub-id-type="pmcid">PMC523569</pub-id></mixed-citation></ref><ref id="jiae289-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hodeib</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Herberg</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Levin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sancho-Shimizu</surname><given-names>V</given-names></string-name></person-group>. <article-title>Human genetics of meningococcal infections</article-title>. <source>Hum Genet</source><year>2020</year>; <volume>139</volume>:<fpage>961</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">32067109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00439-020-02128-4</pub-id><pub-id pub-id-type="pmcid">PMC7272491</pub-id></mixed-citation></ref><ref id="jiae289-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kumar</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Pouw</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Autio</surname><given-names>MI</given-names></string-name>, <etal>et al</etal></person-group><article-title>Variation in CFHR3 determines susceptibility to meningococcal disease by controlling factor H concentrations</article-title>. <source>Am J Hum Genet</source><year>2022</year>; <volume>109</volume>:<fpage>1680</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">36007525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2022.08.001</pub-id><pub-id pub-id-type="pmcid">PMC9502058</pub-id></mixed-citation></ref><ref id="jiae289-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kasper</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Rice</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>McCormick</surname><given-names>WM</given-names></string-name></person-group>. <article-title>Bactericidal antibody in genital infection due to <italic toggle="yes">Neisseria gonorrhoeae</italic></article-title>. <source>J Infect Dis</source><year>1977</year>; <volume>135</volume>:<fpage>243</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">402426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/135.2.243</pub-id></mixed-citation></ref><ref id="jiae289-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Buchanan</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Eschenbach</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Knapp</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Holmes</surname><given-names>KK</given-names></string-name></person-group>. <article-title>Gonococcal salpingitis is less likely to recur with <italic toggle="yes">Neisseria gonorrhoeae</italic> of the same principal outer membrane protein antigenic type</article-title>. <source>Am J Obstet Gynecol</source><year>1980</year>; <volume>138</volume>:<fpage>978</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">6781350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0002-9378(80)91091-1</pub-id></mixed-citation></ref><ref id="jiae289-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ruiz Garc&#237;a</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sohn</surname><given-names>W-Y</given-names></string-name>, <string-name name-style="western"><surname>Seib</surname><given-names>KL</given-names></string-name>, <etal>et al</etal></person-group><article-title>Looking beyond meningococcal B with the 4CMenB vaccine: the <italic toggle="yes">Neisseria</italic> effect</article-title>. <source>NPJ Vaccines</source><year>2021</year>; <volume>6</volume>:<fpage>130</fpage>.<pub-id pub-id-type="pmid">34716336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-021-00388-3</pub-id><pub-id pub-id-type="pmcid">PMC8556335</pub-id></mixed-citation></ref><ref id="jiae289-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Petousis-Harris</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Paynter</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Morgan</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group><article-title>Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study</article-title>. <source>Lancet</source><year>2017</year>; <volume>390</volume>:<fpage>1603</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">28705462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)31449-6</pub-id></mixed-citation></ref><ref id="jiae289-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Paynter</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Goodyear-Smith</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Morgan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Saxton</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Black</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Petousis-Harris</surname><given-names>H</given-names></string-name></person-group>. <article-title>Effectiveness of a group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study</article-title>. <source>Vaccines (Basel)</source><year>2019</year>; <volume>7</volume>:<fpage>5</fpage>.<pub-id pub-id-type="pmid">30621260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines7010005</pub-id><pub-id pub-id-type="pmcid">PMC6466174</pub-id></mixed-citation></ref><ref id="jiae289-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Longtin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dion</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Simard</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group><article-title>Possible impact of wide-scale vaccination against serogroup B <italic toggle="yes">Neisseria meningitidis</italic> on gonorrhea incidence rates in one region of Quebec, Canada</article-title>. <source>Open Forum Infect Dis</source><year>2017</year>; <volume>4</volume>:<fpage>S734</fpage>&#8211;<lpage>5</lpage>.</mixed-citation></ref><ref id="jiae289-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abara</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>Bernstein</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>FMT</given-names></string-name>, <etal>et al</etal></person-group><article-title>Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study</article-title>. <source>Lancet Infect Dis</source><year>2022</year>; <volume>22</volume>:<fpage>1021</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">35427490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(21)00812-4</pub-id><pub-id pub-id-type="pmcid">PMC10227473</pub-id></mixed-citation></ref><ref id="jiae289-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Giles</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Andraweera</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group><article-title>Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study</article-title>. <source>Lancet Infect Dis</source><year>2022</year>; <volume>22</volume>:<fpage>1011</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">35427492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(21)00754-4</pub-id></mixed-citation></ref><ref id="jiae289-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bruxvoort</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Lewnard</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>LH</given-names></string-name>, <etal>et al</etal></person-group><article-title>Prevention of <italic toggle="yes">Neisseria gonorrhoeae</italic> with meningococcal B vaccine: a matched cohort study in southern California</article-title>. <source>Clin Infect Dis</source><year>2023</year>; <volume>76</volume>:<fpage>e1341</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">35642527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciac436</pub-id></mixed-citation></ref><ref id="jiae289-B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robison</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Leman</surname><given-names>RF</given-names></string-name></person-group>. <article-title>Association of group B meningococcal vaccine receipt with reduced gonorrhea incidence among university students</article-title>. <source>JAMA Netw Open</source><year>2023</year>; <volume>6</volume>:<fpage>e2331742</fpage>.<pub-id pub-id-type="pmid">37651146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.31742</pub-id><pub-id pub-id-type="pmcid">PMC10472183</pub-id></mixed-citation></ref><ref id="jiae289-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raccagni</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Galli</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Spagnuolo</surname><given-names>V</given-names></string-name>, <etal>et al</etal></person-group><article-title>Meningococcus B vaccination effectiveness against <italic toggle="yes">Neisseria gonorrhoeae</italic> infection in people living with HIV: a case-control study</article-title>. <source>Sex Transm Dis</source><year>2023</year>; <volume>50</volume>:<fpage>247</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">36728240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/OLQ.0000000000001771</pub-id></mixed-citation></ref><ref id="jiae289-B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Looker</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Booton</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Begum</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group><article-title>The potential public health impact of adolescent 4CMenB vaccination on <italic toggle="yes">Neisseria gonorrhoeae</italic> infection in England: a modelling study</article-title>. <source>BMC Public Health</source><year>2023</year>; <volume>23</volume>:<fpage>1</fpage>.<pub-id pub-id-type="pmid">36624437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-022-14670-z</pub-id><pub-id pub-id-type="pmcid">PMC9829524</pub-id></mixed-citation></ref><ref id="jiae289-B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leduc</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Connolly</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Begum</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group><article-title>The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against <italic toggle="yes">Neisseria gonorrhoeae</italic></article-title>. <source>PLoS Pathog</source><year>2020</year>; <volume>16</volume>:<fpage>e1008602</fpage>.<pub-id pub-id-type="pmid">33290434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1008602</pub-id><pub-id pub-id-type="pmcid">PMC7748408</pub-id></mixed-citation></ref><ref id="jiae289-B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reyes Diaz</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lastre Gonzalez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cuello</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group><article-title>VA-MENGOC-BC vaccination induces serum and mucosal anti <italic toggle="yes">Neisseria gonorrhoeae</italic> immune responses and reduces the incidence of gonorrhea</article-title>. <source>Pediatr Infect Dis J</source><year>2021</year>; <volume>40</volume>:<fpage>375</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">33591079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/INF.0000000000003047</pub-id></mixed-citation></ref><ref id="jiae289-B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>P&#233;rez</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Lastre</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lapinet</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group><article-title>Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine</article-title>. <source>Infect Immun</source><year>2001</year>; <volume>69</volume>:<fpage>4502</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">11401992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.69.7.4502-4508.2001</pub-id><pub-id pub-id-type="pmcid">PMC98525</pub-id></mixed-citation></ref><ref id="jiae289-B43"><label>43</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Molina</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bercot</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Assoumou</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group><article-title>ANRS 174 DOXYVAC: an open-label randomized trial to prevent STIs in MSM on PrEP</article-title>. <comment>In: 30th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 19&#8211;22 February 2023</comment>.</mixed-citation></ref><ref id="jiae289-B44"><label>44</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Molina</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bercot</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Assoumou</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group><article-title>Final results of ANRS 174 DOXYVAC: a randomized trial to prevent STI in MSM on PrEP</article-title>. <comment>In: 31st Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, 3&#8211;6 March 2024</comment>.</mixed-citation></ref><ref id="jiae289-B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O&#8217;Ryan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stoddard</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Toneatto</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wassil</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dull</surname><given-names>PM</given-names></string-name></person-group>. <article-title>A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program</article-title>. <source>Drugs</source><year>2014</year>; <volume>74</volume>:<fpage>15</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">24338083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40265-013-0155-7</pub-id><pub-id pub-id-type="pmcid">PMC3890039</pub-id></mixed-citation></ref><ref id="jiae289-B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Giuliani</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Adu-Bobie</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Comanducci</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group><article-title>A universal vaccine for serogroup B meningococcus</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2006</year>; <volume>103</volume>:<fpage>10834</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">16825336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0603940103</pub-id><pub-id pub-id-type="pmcid">PMC2047628</pub-id></mixed-citation></ref><ref id="jiae289-B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hadad</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jacobsson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pizza</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group><article-title>Novel meningococcal 4CMenB vaccine antigens&#8212;prevalence and polymorphisms of the encoding genes in <italic toggle="yes">Neisseria gonorrhoeae</italic></article-title>. <source>APMIS</source><year>2012</year>; <volume>120</volume>:<fpage>750</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">22882265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0463.2012.02903.x</pub-id></mixed-citation></ref><ref id="jiae289-B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Semchenko</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Borrow</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Seib</surname><given-names>KL</given-names></string-name></person-group>. <article-title>The serogroup B meningococcal vaccine Bexsero elicits antibodies to <italic toggle="yes">Neisseria gonorrhoeae</italic></article-title>. <source>Clin Infect Dis</source><year>2019</year>; <volume>69</volume>:<fpage>1101</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="pmid">30551148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciy1061</pub-id><pub-id pub-id-type="pmcid">PMC6743822</pub-id></mixed-citation></ref><ref id="jiae289-B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Semchenko</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Day</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Seib</surname><given-names>KL</given-names></string-name></person-group>. <article-title>The <italic toggle="yes">Neisseria gonorrhoeae</italic> vaccine candidate NHBA elicits antibodies that are bactericidal, opsonophagocytic and that reduce gonococcal adherence to epithelial cells</article-title>. <source>Vaccines (Basel)</source><year>2020</year>; <volume>8</volume>:<fpage>219</fpage>.<pub-id pub-id-type="pmid">32414194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8020219</pub-id><pub-id pub-id-type="pmcid">PMC7349534</pub-id></mixed-citation></ref><ref id="jiae289-B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hammer</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <etal>et al</etal></person-group><article-title>Experimental vaccine induces Th1-driven immune responses and resistance to <italic toggle="yes">Neisseria gonorrhoeae</italic> infection in a murine model</article-title>. <source>Mucosal Immunol</source><year>2017</year>; <volume>10</volume>:<fpage>1594</fpage>&#8211;<lpage>608</lpage>.<pub-id pub-id-type="pmid">28272393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mi.2017.11</pub-id><pub-id pub-id-type="pmcid">PMC5591041</pub-id></mixed-citation></ref><ref id="jiae289-B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beernink</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Ispasanie</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Ram</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Moe</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Granoff</surname><given-names>DM</given-names></string-name></person-group>. <article-title>A meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and overexpressed factor H binding protein elicits gonococcal bactericidal antibodies</article-title>. <source>J Infect Dis</source><year>2019</year>; <volume>219</volume>:<fpage>1130</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">30346576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiy609</pub-id><pub-id pub-id-type="pmcid">PMC6420169</pub-id></mixed-citation></ref><ref id="jiae289-B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matthias</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Connolly</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Begum</surname><given-names>AA</given-names></string-name>, <etal>et al</etal></person-group><article-title>Meningococcal detoxified outer membrane vesicle vaccines enhance gonococcal clearance in a murine infection model</article-title>. <source>J Infect Dis</source><year>2022</year>; <volume>225</volume>:<fpage>650</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">34498079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiab450</pub-id><pub-id pub-id-type="pmcid">PMC8844591</pub-id></mixed-citation></ref><ref id="jiae289-B53"><label>53</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>MacLennan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ram</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Freixero</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Rollier</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kaminski</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Delany-Moretlwe</surname><given-names>S</given-names></string-name></person-group>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.birmingham.ac.uk/research/immunology-immunotherapy/research/bactivac/funded-pump-priming-projects-awardees/prof-calman-maclennan.aspx" ext-link-type="uri">https://www.birmingham.ac.uk/research/immunology-immunotherapy/research/bactivac/funded-pump-priming-projects-awardees/prof-calman-maclennan.aspx</ext-link>. Accessed 7 April 2023.</mixed-citation></ref><ref id="jiae289-B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group><article-title>Design and immune characterization of a novel <italic toggle="yes">Neisseria gonorrhoeae</italic> DNA vaccine using bacterial ghosts as vector and adjuvant</article-title>. <source>Vaccine</source><year>2018</year>; <volume>36</volume>:<fpage>4532</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29914847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.06.006</pub-id></mixed-citation></ref><ref id="jiae289-B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>G</given-names></string-name></person-group>. <article-title>Enhancement of immune responses by co-administration of bacterial ghosts-mediated <italic toggle="yes">Neisseria gonorrhoeae</italic> DNA vaccines</article-title>. <source>J Appl Microbiol</source><year>2021</year>; <volume>130</volume>:<fpage>1770</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">32770820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jam.14815</pub-id></mixed-citation></ref><ref id="jiae289-B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fegan</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Calmettes</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Islam</surname><given-names>EA</given-names></string-name>, <etal>et al</etal></person-group><article-title>Utility of hybrid transferrin binding protein antigens for protection against pathogenic <italic toggle="yes">Neisseria</italic> species</article-title>. <source>Front Immunol</source><year>2019</year>; <volume>10</volume>:<fpage>247</fpage>.<pub-id pub-id-type="pmid">30837995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00247</pub-id><pub-id pub-id-type="pmcid">PMC6389628</pub-id></mixed-citation></ref><ref id="jiae289-B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gulati</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pennington</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Czerwinski</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group><article-title>Preclinical efficacy of a lipooligosaccharide peptide mimic candidate gonococcal vaccine</article-title>. <source>mBio</source><year>2019</year>; <volume>10</volume>:<fpage>e02552-19</fpage>.<pub-id pub-id-type="pmid">31690678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.02552-19</pub-id><pub-id pub-id-type="pmcid">PMC6831779</pub-id></mixed-citation></ref><ref id="jiae289-B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gala</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Zaman</surname><given-names>RU</given-names></string-name>, <string-name name-style="western"><surname>D'Souza</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Zughaier</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Novel whole-cell inactivated <italic toggle="yes">Neisseria gonorrhoeae</italic> microparticles as vaccine formulation in microneedle-based transdermal immunization</article-title>. <source>Vaccines (Basel)</source><year>2018</year>; <volume>6</volume>:<fpage>60</fpage>.<pub-id pub-id-type="pmid">30181504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines6030060</pub-id><pub-id pub-id-type="pmcid">PMC6161099</pub-id></mixed-citation></ref><ref id="jiae289-B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maurakis</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Cornelissen</surname><given-names>CN</given-names></string-name></person-group>. <article-title>Recent progress towards a gonococcal vaccine</article-title>. <source>Front Cell Infect Microbiol</source><year>2022</year>; <volume>12</volume>:<fpage>881392</fpage>.<pub-id pub-id-type="pmid">35480233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2022.881392</pub-id><pub-id pub-id-type="pmcid">PMC9038166</pub-id></mixed-citation></ref><ref id="jiae289-B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ram</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gulati</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>LA</given-names></string-name>, <etal>et al</etal></person-group><article-title>A novel sialylation site on <italic toggle="yes">Neisseria gonorrhoeae</italic> lipooligosaccharide links heptose II lactose expression with pathogenicity</article-title>. <source>Infect Immun</source><year>2018</year>; <volume>86</volume>:<fpage>e00285</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">29844237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.00285-18</pub-id><pub-id pub-id-type="pmcid">PMC6056883</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>